



(51) International Patent Classification:

C07D 217/26 (2006.01) **C07D 487/08** (2006.01)
C07D 401/04 (2006.01) **C07D 487/10** (2006.01)
C07D 401/10 (2006.01) **C07D 491/10** (2006.01)
C07D 401/14 (2006.01) **A61P 7/02** (2006.01)
C07D 413/14 (2006.01) **A61K 31/4725** (2006.01)
C07D 471/10 (2006.01) **A61K 31/437** (2006.01)
C07D 487/04 (2006.01) **A61K 31/4375** (2006.01)

(21) International Application Number:

PCT/US2012/059969

(22) International Filing Date:

12 October 2012 (12.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/547,292 14 October 2011 (14.10.2011) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543-4000 (US).(72) Inventors: **ORWAT, Michael J.**; c/o Bristol-Myers
Squibb Company, 311 Pennington-Rocky Hill Road, Pen-
nington, New Jersey 08534 (US). **PINTO, Donald J.P.**;
c/o Bristol-Myers Squibb Company, 311 Penning-
ton-Rocky Hill Road, Pennington, New Jersey 08534 (US).
SMITH II, Leon M.; c/o Bristol-Myers Squibb Company,
311 Pennington-Rocky Hill Road, Pennington, New Jersey
08534 (US). **SRIVASTAVA, Shefali**; c/o Syngene Inter-
national Limited, Biocon Park, Plot Nos. 2&3, Bommas-
andra IV Phase Jigani Link Road, Bangalore, Karnataka
560099 (IN).(74) Agents: **LIU, Hong** et al.; Bristol-Myers Squibb Company,
P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS



(57) **Abstract:** The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.